Dipharma Francis

  • Dipharma's CGMP pilot plant, located in Mereto di Tomba (Italy)
  • Cutting-edge CGMP kilolab, at Dipharma Inc., US
  • Dipharma's state-of-the-art R&D laboratory
About Dipharma Francis

The Dipharma Group is a global CDMO and a leading manufacturer of APIs, New Chemical Entities (NCE), and advanced Intermediates for Generic and Contract Manufacturing markets, offering about 40 APIs with DMFs registered worldwide.  
Thanks to a workforce of about 600 skilled and highly committed employees, supported by four state-of-the-art CGMP facilities, located in the U.S.A. and Italy, plus commercial sales offices in Italy, the U.S.A. and China, Dipharma is strategically positioned to meet the dynamic needs of the pharmaceutical industry.  
Our fully-equipped Research and Development Centers, supported by the internal Intellectual Property department, drive innovation by developing cutting-edge chemical processes and crystalline forms tailored to meet the unique requirements of our customers. 
Since 1970, Dipharma has managed to achieve a positive unbroken record of inspections by the major Regulatory Agencies and the CGMP manufacturing sites are equipped to supply quantities from laboratory to industrial scale, covering the entire lifecycle of a pharmaceutical substance. 

Dipharma's core technologies are: High-pressure hydrogenation, Nitration, Nitroesterification, Azide chemistry, Borane reductions, Cross-coupling reactions, Curtius reaction, Dissolving metal reduction, Enzymatic chemistry, Epichlorohydrin chemistry, Hoffman reaction, Hydrogen peroxide oxidations, Carbohydrate chemistry, Enantioselective reactions, Use of nitroalkanes (Henry reaction), Wolff-Kishner reduction. 

The Dipharma Group has the right size and variety of scale-up capabilities to act as a global player and manage processes efficiently while offering flexibility and agility to promptly solve any challenge. 

Experience you can trust 

Certifications
  • IT
  • 2015
    On CPHI since
  • 3
    Certificates
  • 250 - 499
    Employees
Company types
Manufacturer/Innovator
Primary activities
API Producer
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
Intermediates Manufacturer
Contact info
Meet us at

CPHI Milan 2024

Fiera Milano, Italy
08 Oct 2024 - 10 Oct 2024

Products from Dipharma Francis (41)

  • Aminocaproic Acid

    Product Aminocaproic Acid

    Dipharma manufactures wide range of Active Pharmaceutical Ingredients which includes Aminocaproic Acid. It belongs to new products category. Therapeutic category: Treatment of bleeding disorders. Contact us for more information.

  • Amitriptyline Hydrochloride

    Product Amitriptyline Hydrochloride

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Amitriptyline Hydrochloride. It belongs to commercial products category. Therapeutic category: Antidepressant. Contact us for more information.
  • Benserazide Hydrochloride

    Product Benserazide Hydrochloride

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Benserazide Hydrochloride. It belongs to new products category. Therapeutic category: Antiparkinson. Contact us for more information.
  • Biperiden  Hydrochloride

    Product Biperiden Hydrochloride

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Biperiden Hydrochloride. It belongs to new products category. Therapeutic category: Antiparkinson. Contact us for more information.
  • Bupropion Hydrochloride

    Product Bupropion Hydrochloride

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Bupropion Hydrochloride. It belongs to commercial products category. Therapeutic category: Antidepressant. Contact us for more information.
  • Chenodeoxycholic Acid*

    Product Chenodeoxycholic Acid*

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Chenodeoxycholic Acid*. It belongs to new products category. Therapeutic category: Bile Stone Therapy, Plain antitussives. Contact us for more information.

    * only for specific markets. See our web site
  • Crisaborole

    Product Crisaborole

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Crisaborole. It belongs to new products category. Therapeutic category: Treatment of atopic dermatitis and psoriasis. Contact us for more information.
  • Cyclobenzaprine Hydrochloride

    Product Cyclobenzaprine Hydrochloride

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Cyclobenzaprine Hydrochloride. It belongs to commercial products category. Therapeutic category: Muscle Relaxant. Contact us for more information.
  • Dapsone

    Product Dapsone

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Dapsone. It belongs to new products category. Therapeutic category: Antibacterial. Contact us for more information.
  • Dexlansoprazole Anhydrous Crystalline

    Product Dexlansoprazole Anhydrous Crystalline

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Dexlansoprazole Anhydrous Crystalline. It belongs to new products category. Therapeutic category: Antiulcerative. Contact us for more information.
  • Diclofenac Epolamine

    Product Diclofenac Epolamine

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Diclofenac Epolamine. It belongs to new products category. Therapeutic category: Anti-inflammatory. Contact us for more information.
  • Diclofenac Potassium

    Product Diclofenac Potassium

    Dipharma manufactures wide range of active pharmaceutical ingredients which includes Diclofenac Potassium. It belongs to commercial products category. Therapeutic category: Anti-inflammatory. Contact us for more information.

Dipharma Francis Resources (16)

  • News Successful FDA Inspection at Dipharma Facility in Kalamazoo, MI, USA

    Dipharma Inc. has been inspected by the US FDA and has received the EIR, satisfactorily closing the inspection process. The Company expands its range of CGMP services to include small-scale commercial APIs.
  • Video The Dipharma Group - Experience you can trust

    The Dipharma Group is a global Contract Development and Manufacturing Organization (CDMO) and a leading manufacturer of Active Pharmaceutical Ingredients (APIs), New Chemical Entities (NCE), and advanced Intermediates for Generic and Contract Manufacturing markets, offering APIs with DMFs registered worldwide. 

  • News Dipharma expands its Italian R&D Center to increase its analytical services

    The Company strengthens its analytical R&D capabilities, to better support its customers operating in the CDMO and Generics market.

  • Video Dipharma's CGMP pilot plant in Mereto di Tomba, Italy

    The CGMP pilot plant located in our production site of Mereto (Italy) is equipped with cutting-edge technologies, providing powerful tools to supply from early drug development up to the market. The pilot plant consists of two production lines, each equipped with 2 stainless steel and 2 glass-lined reactors and can produce batches ranging from 5 to 50 kilograms. 
    Our state-of-the-art equipment, combined with demonstrated expertise and flexibility, makes Dipharma the optimal choice to support your projects. 


    EXPERIENCE YOU CAN TRUST.
  • News Dipharma completes second phase of CGMP expansion at its Kalamazoo site

    The Company continues to strengthen its capabilities in the North American market
  • Brochure Dipharma's Catalogue APIs

    Dipharma develops proprietary chemical processes and alternative solutions to support the generic API industry.Our customers can rely on a true turnkey service, where commercially competitive products are promptly conceived and manufactured in full compliance with third-party intellectual property rights.
    Along with quality, confidentiality, safety and meeting deadlines, we ensure a well-established and reliable supply chain for your peace of mind. 
    Our current product portfolio comprises over 40 high quality APIs.
  • News Dipharma receives GMP certification from Brazilian ANVISA

    The Baranzate site (Italy) is the first Dipharma manufacturing facilityto receive Anvisa certification
  • Brochure Dipharma's Exclusive Synthesis

    Achieve your goals more easily, safely and rapidly.The ability to develop innovative synthetic processes, combined with proven know-how in the handling of hazardous chemicals and reactions, makes Dipharma your optimal choice for Exclusive Synthesis services from discovery to the commercial stage.We provide you with tailor-made development and manufacturing of new and complex molecules, all the required analytical and regulatory assistance, as well as support in pre-formulation activities.
  • News Regulatory authorization for the new line at cGMP pilot plant

    Thanks to the approval by the Italian Medicines Agency (AIFA),the Company increases its efficiency and is able to face the growing demand for its services
  • News Dipharma receives EcoVadis Silver Medal

    EcoVadis has rated Dipharma Francis’s performance among the top 25% of all organizations surveyed.
  • News Merger of Kalexsyn Inc. into Dipharma Inc.

    The merger represents the last step of Kalexsyn’s integration into the Dipharma Group
  • News Kalexsyn appoints Brian Eklov as new CEO

    Kalexsyn Inc. announced that its Board of Directors appointed Brian Eklov to succeed Robert Gadwood, who is retiring, as Chief Executive Officer and Board member.
  • News Dipharma installs a new trigeneration unit

    The new plant brings significant positive impact on the environment and sustainable development
  • News Dipharma builds cGMP manufacturing suite at US subsidiary

    Italy’s Dipharma Francis has completed construction of a new cGMP manufacturing suite at its US subsidiary, Kalexsyn, strengthening its service offering and ensuring continuity across the product lifecycle from preclinical to commercialisation , the contract research and development organization announced Monday.
  • News Dipharma Francis S.r.l. announces changes in the leadership positions

    Dipharma Francis S.r.l., (Dipharma), a leading European manufacturer of Active Pharmaceutical Ingredients, announced a series of changes in the leadership positions following the retirement of Mrs. Barbara Geinoz-Biazzi, Chairman.